Geron: 3 Key Takeaways for Long-Term Investors
Operating expenses fell 9% year to date, and $339 million in cash leaves Geron room to pursue hematology deals.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
